Advertisement
Advertisement
U.S. markets close in 3 hours 11 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Dermata Therapeutics, Inc. (DRMA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1989+0.0062 (+3.22%)
As of 12:44PM EST. Market open.
Advertisement

Dermata Therapeutics, Inc.

3525 Del Mar Heights Road
Suite 332
San Diego, CA 92130
United States
858 800 2543
https://www.dermatarx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. Gerald T. ProehlFounder, Pres, CEO & Chairman135.91kN/A1959
Mr. David F. HaleCo-Founder & Lead Independent Director27.19kN/A1949
Ms. Kyri K. Van Hoose CPA, M.B.A.Sr. VP & CFO265.05kN/A1979
Dr. Christopher J. Nardo M.P.H., Ph.D.Sr. VP & Chief Devel. Officer356.4kN/A1965
Mr. Sean ProehlSr. Director of Legal & Bus. Devel.N/AN/AN/A
Dr. Maria Bedoya Toro Munera M.B.A., Ph.D.Sr. VP of Regulatory Affairs & Quality AssuranceN/AN/A1952
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Corporate Governance

Dermata Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement